September 12, 2025OncoTargets and TherapyOpen Access

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

View Full Paper

Ask AI

Bookmark

Despite initial treatment with TROP2 antibody-drug conjugate, the patient's disease progressed with drug resistance.
The case involved a 33-year-old woman who experienced rapid metastasis to the liver and lungs, with a progression-free survival of 5.6 months.
Therapeutic strategies for epithelial-myoepithelial carcinoma remain limited due to its rarity and challenging treatment response.
The patient's treatment included a complex regimen of chemotherapy followed by radiofrequency ablation and TROP2 therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Case report highlights TROP2 treatment in a patient with epithelial-myoepithelial carcinoma, indicating challenges in managing metastasis.

Zhao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case report highlights TROP2 treatment in a patient with epithelial-myoepithelial carcinoma, indicating challenges in managing metastasis.